Funding for this research was provided by:
Kuwait Ministry of Health (Kuwait Ministry of Health)
Received: 6 April 2021
Accepted: 10 August 2021
First Online: 30 August 2021
: The study was approved by the University of Manchester Research Ethics Committee (UREC)–Project Number: 2018–3990–7300, and permissions to conduct research at the Jordanian, Omani, and Kuwaiti national drug authorities were obtained from each authority. All participants gave informed consent, and each participant was assigned a number and all quotes were anonymised to prevent statements from being traced back to individuals.
: Not applicable.
: This is an independent study undertaken as part of a PhD, and the authors were not asked nor commissioned to inform recommendations for implementing a pharmacovigilance policy for Kuwait’s national drug authority. However, it is projected that the recommendations generated from this research will be proposed to Kuwait’s national drug authority for consideration.